Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urea Cycle01:23

Urea Cycle

49.8K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
49.8K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

344
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
344
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

297
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
297
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional profiling of 2,193 ASS1 missense variants: Insights into variant pathogenicity and epistatic interactions in citrullinemia type I.

PLoS genetics·2026
Same author

Pediatric liver transplantation for metabolic diseases: a single-center experience.

World journal of pediatrics : WJP·2026
Same author

Resources and care structures for management of urea cycle disorders in Japan and the United States: A system-level comparison.

Molecular genetics and metabolism·2026
Same author

Predicting epistasis across proteins by structural logic.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Propionic acidemia and methylmalonic aciduria: A portrait of the first 3 years-Admissions and complications.

Molecular genetics and metabolism·2025
Same author

Two commonly reported incidental variants in OTC are associated with late-onset disease.

HGG advances·2025

Related Experiment Video

Updated: Jan 17, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.8K

Current Treatment Modalities for Urea Cycle Disorders.

Nicholas Ah Mew1, Uta Lichter-Konecki2

  • 1Center for Precision Medicine and Genomics Research, Children's National Hospital, Washington, DC, USA.

Paediatric Drugs
|September 21, 2025
PubMed
Summary

Urea cycle disorders disrupt nitrogen detoxification, causing toxic ammonia buildup. Recent advancements include enzyme and gene therapies, complementing traditional treatments like carglumic acid.

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K
Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.9K

Related Experiment Videos

Last Updated: Jan 17, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.8K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K
Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.9K

Area of Science:

  • Biochemistry
  • Metabolic pathways
  • Nitrogen metabolism

Background:

  • The urea cycle is crucial for removing toxic ammonia from the body.
  • Deficiencies in urea cycle components lead to hyperammonemia, particularly harmful to the brain.
  • Traditional treatments include dietary changes, supplements, and liver transplantation.

Purpose of the Study:

  • To review current and emerging treatment options for urea cycle disorders (UCDs).
  • To highlight recent therapeutic advancements in managing UCDs.

Main Methods:

  • Literature review of established and novel UCD treatments.
  • Analysis of therapeutic strategies including pharmacologic, enzymatic, and genetic approaches.

Main Results:

  • Carglumic acid is an established treatment for N-acetylglutamate synthase deficiency.
  • Enzyme therapy for arginase deficiency and gene therapy for ornithine transcarbamylase deficiency represent significant progress.
  • A combination of traditional and novel therapies is often employed.

Conclusions:

  • The landscape of UCD treatment has evolved significantly with new therapeutic modalities.
  • Continued research and development are essential for improving patient outcomes in UCDs.
  • Personalized treatment strategies are becoming increasingly important for managing UCDs.